Answers are grounded in this paper and cite their sources.
In recent years, significant progress has been made in developing tools that consist of programmable RNA binding proteins and m 6 A-erasers to selectively demethylate m 6 A at specific sites. Especially, timing-controllable demethylation tools using stimulus-inducible dimerization show promise in understanding the impact of individual m 6 A modifications on dynamic physiological processes. However, a critical issue with these technologies is the possible off-target effects, wherein wild-type m 6 A-erasers constituting the tools may decrease methylation levels at sites other than the intended target m 6 A. In this study, we addressed this issue by reducing the intrinsic RNA-binding ability of m 6 A-erasers to prevent off-target effects and by fusing with PUF RNA-binding protein to provide recognition ability of arbitrary RNA sequences. Taking advantage of the reduced RNA-binding ability of the m 6 A-erasers themselves, we employed a rapamycin-based switching system in the linker connecting the PUF and m 6 A-eraser domains. The resulting m 6 A-erasers exhibited superior precision in demethylating targeted sites while minimizing off-target effects, presenting a novel approach for precise temporal control over m 6 A modification dynamics.
No takes yet. Share an insight, caveat, or question.
Otonari et al. (2024) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: